Alopecia Areata And Atopic Dermatitis: Common Mechanisms And Emerging Therapeutics

April 2026 in “ Journal of Inflammation Research ”

Alice Tang, Grace Rachko, Flavia Manzo Margiotta, Jasmine Levine, Ester Del Duca, Benjamin Ungar

alopecia areata atopic dermatitis cytokine dysregulation JAK-STAT pathway regulatory T cell dysfunction IL-4 IL-13 IgE JAK inhibitors baricitinib dupilumab immune homeostasis AA AD Janus kinase inhibitors

From the encyclopedia

Alopecia Areata →

autoimmune disorder causing patchy hair loss

Baricitinib →

JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

Studysummary This narrative review highlights the shared immunopathogenesis of alopecia areata and atopic dermatitis and discusses approved and investigational therapies that target common pathways, suggesting a future for personalized treatment strategies.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

Alopecia areata (AA) and atopic dermatitis (AD) share significant immunological overlap, with both conditions involving cytokine dysregulation through the JAK-STAT pathway and regulatory T cell dysfunction. Up to 40% of AA patients have atopic comorbidities, and both diseases share genetic susceptibility loci. Key shared biomarkers include elevated IL-4, IL-13, and IgE. JAK inhibitors like baricitinib and dupilumab have shown efficacy in treating both conditions by targeting these pathways. Emerging therapies aim to restore immune homeostasis, offering potential disease-modifying interventions for AA and AD.

View this study on dovepress.com →

Discuss this study in the Community →

Research cited in this study

43 / 43 results

research Immune Therapies for Alopecia Areata: Evidence and New Perspectives

5 citations , October 2025 in “Expert Review of Clinical Immunology”

This article reviews current and emerging treatments for alopecia areata, emphasizing the need for biomarker-driven patient stratification to optimize therapeutic strategies and reduce potential side effects; it reports no new clinical findings.

research Treatment Outcomes and Considerations for Topical Immunotherapy in Patients with Alopecia Totalis and Alopecia Universalis

July 2025 in “Frontiers in Medicine”

This study found that topical immunotherapy is effective for treating severe alopecia areata, though patient responses can vary, highlighting the importance of individualized treatment approaches and prolonged therapy to optimize outcomes.

research Immune-Mediated Disorders in Patients With Alopecia Areata: Systematic Review and Meta-Analysis

7 citations , July 2025 in “International Journal of Dermatology”

This meta-analysis found that patients with alopecia areata have significantly higher odds of also having immune-mediated diseases such as atopic dermatitis, autoimmune thyroiditis, inflammatory bowel disease, systemic lupus erythematosus, and vitiligo, suggesting a need for comprehensive screening and interdisciplinary management.

research Lessons from TNF-Alpha Inhibitor-Induced Alopecia Areata: Does TNF-Alpha Operate as a Hair Follicle Immune Privilege Guardian Under Inflammatory Conditions?

2 citations , June 2025 in “Journal of Investigative Dermatology”

research Oral Minoxidil Treatment of Alopecia Areata

3 citations , June 2025 in “Journal of the American Academy of Dermatology”

research A Translational Approach to Improve Therapeutics in Atopic Dermatitis and Beyond

4 citations , May 2025 in “The Journal of Immunology”

This review explores how molecular profiling in atopic dermatitis has led to new therapeutic developments, detailing approved and potential treatments, and discusses similar advances in alopecia areata; it reports no new results.

research Real-World Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients

April 2025 in “Acta Dermato Venereologica”

In this real-world study, JAK inhibitors like abrocitinib and tofacitinib led to substantial hair regrowth in 61% of alopecia areata patients over a median of 16 months, with 75% of non-responders achieving regrowth after switching medications; however, two serious adverse events were noted.

research A Case of Unexpected Successful Treatment of Alopecia Areata With Tralokinumab in a Patient With Atopic Dermatitis

2 citations , March 2025 in “International Journal of Dermatology”

In this case report, the authors described a 46-year-old woman with severe atopic dermatitis and alopecia areata, who experienced significant improvements in both conditions after treatment with the interleukin-13 blocker tralokinumab, suggesting a potential therapeutic role for targeting type 2 cytokine IL-13 in such cases.

research Global Burden of Alopecia Areata and Associated Diseases: A Trend Analysis From 1990 to 2021

February 2025 in “PubMed”

This study found that although the global incidence of alopecia areata has risen since 1990, age-standardized rates have slightly decreased, with significant comorbidity associations varying by region.

research British Association of Dermatologists Living Guideline for Managing People with Alopecia Areata 2024

20 citations , October 2024 in “British Journal of Dermatology”

In this updated guideline, the British Association of Dermatologists' expert group provided 49 management recommendations for alopecia areata and highlighted future research priorities, aiming to improve care for individuals affected by this condition.

research Alopecia Areata Exhibits Cutaneous And Systemic OX40 Activation Across Atopic Backgrounds

August 2024 in “Allergy”

This study identified distinct immune differences in patients with alopecia areata, particularly those with atopic backgrounds, and highlighted the OX40 axis as a potential therapeutic target for the condition.

research Comparative Efficacy of Oral Janus Kinase Inhibitors and Biologics in Adult Alopecia Areata: A Systematic Review and Bayesian Network Meta-Analysis

20 citations , January 2024 in “Journal of the European Academy of Dermatology and Venereology”

This study conducted a meta-analysis and found that among therapies for alopecia areata, baricitinib_4 mg was most likely to be effective, followed by ritlecitinib and ivarmacitinib, while other treatments like dupilumab and secukinumab were less effective.

research Tralokinumab as a Therapeutic Option for Patients with Concurrent Atopic Dermatitis and Alopecia Areata

9 citations , January 2024 in “International Journal of Dermatology”

Tralokinumab may help improve symptoms of atopic dermatitis and alopecia areata.

research Inhibition of T-Cell Activity in Alopecia Areata: Recent Developments and New Directions

4 citations , November 2023 in “Frontiers in immunology”

In this narrative review, researchers outlined the role of T cells in the autoimmune pathogenesis of alopecia areata and highlighted ongoing research into therapeutic pathways, beyond current JAK inhibitors, aimed at developing new treatments for the disease.

research Alopecia Areata: What's New in the Epidemiology, Comorbidities, and Pathogenesis?

49 citations , October 2023 in “Journal of Dermatological Science”

research Alopecia Areata: Current Treatments and New Directions

57 citations , August 2023 in “American Journal of Clinical Dermatology”

JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.

research Clinical and Genetic Aspects of Alopecia Areata: A Cutting Edge Review

1 citations , June 2023 in “Genes”

This study highlights the genetic complexities in alopecia areata, emphasizing the role of microRNAs and their association with other immune-related diseases, which could inform targeted treatment strategies.

research Janus Kinase Inhibitors For Alopecia Areata

12 citations , June 2023 in “JAMA network open”

In this study of seven randomized clinical trials, JAK inhibitors were associated with improved hair regrowth outcomes in alopecia areata patients compared to placebo, with oral administration being more effective than external application, though longer trials are needed to confirm safety and effectiveness.

research Biomarkers in Alopecia Areata: A Systematic Review and Meta-Analysis

4 citations , April 2023 in “Autoimmunity reviews”

This systematic review and meta-analysis reports that patients with alopecia areata have significantly higher serum levels of IL6 and CRP, and lower levels of vitamin D, compared to healthy controls.

research Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial

227 citations , April 2023 in “The Lancet”

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

research Association of Atopic Dermatitis With Autoimmune Diseases: A Bidirectional and Multivariable Two-Sample Mendelian Randomization Study

12 citations , March 2023 in “Frontiers in immunology”

This study found evidence that atopic dermatitis may increase the risk of developing rheumatoid arthritis, type 1 diabetes, and alopecia areata, but not other autoimmune diseases.

research Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population

75 citations , March 2023 in “JAMA Dermatology”

This study reported that the prevalence of alopecia areata in the US slightly increased from 0.199% to 0.222% between 2016 and 2019, with higher rates observed in women and adults.

research Diverse Role of OX40 on T Cells as a Therapeutic Target for Skin Diseases

30 citations , February 2023 in “Journal of Investigative Dermatology”

OX40-targeted therapies may help treat skin diseases by reducing inflammation and balancing immune responses.

research Scalp Biomarkers During Dupilumab Treatment Support Th2 Pathway Pathogenicity in Alopecia Areata

15 citations , October 2022 in “Allergy”

This study found that dupilumab treatment in alopecia areata significantly suppressed Th2-related markers and increased hair keratin levels, suggesting a potential role of Th2 cytokines in the disease's pathogenesis.

research The Role of Antihistamines and Dupilumab in the Management of Alopecia Areata: A Systematic Review

13 citations , September 2022 in “Journal of Drugs in Dermatology”

This study suggests that antihistamines show promise as adjunct treatments for alopecia areata, but the role of dupilumab needs further investigation due to mixed results regarding hair regrowth and adverse effects.

research An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata

40 citations , August 2022 in “Frontiers in immunology”

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.

research Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers

36 citations , December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology”

This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.

research Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management

290 citations , August 2021 in “Clinical Reviews in Allergy & Immunology”

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

research Immunological Properties of Atopic Dermatitis-Associated Alopecia Areata

57 citations , March 2021 in “International Journal of Molecular Sciences”

This study found that type 2 immunity may play a role in the development of alopecia areata in patients with extrinsic atopic dermatitis, indicating different immunological states compared to non-atopic patients.

research Dupilumab Therapy for Alopecia Areata in Pediatric Patients with Concomitant Atopic Dermatitis

19 citations , January 2021 in “Journal of the American Academy of Dermatology”

This study reported that some pediatric patients with alopecia areata experienced hair regrowth with dupilumab treatment, particularly those with concomitant atopic dermatitis, suggesting dupilumab may be beneficial when traditional therapies fail.

research Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata

134 citations , July 2020 in “Experimental dermatology”

This review discusses immune privilege in anagen hair follicles and its collapse in alopecia areata, emphasizing the importance of restoring this function for effective management and disease relapse prevention.

Efficacy of Antihistamines in Combination with Topical Corticosteroid and Superficial Cryotherapy for Treatment of Alopecia Areata: A Retrospective Cohort Study

research Efficacy of Antihistamines in Combination with Topical Corticosteroid and Superficial Cryotherapy for Treatment of Alopecia Areata: A Retrospective Cohort Study

5 citations , July 2020 in “Journal of the American Academy of Dermatology”

This study suggests that using antihistamines alongside a regimen of topical corticosteroid and superficial cryotherapy may enhance hair regrowth in patients with mild to moderate alopecia areata.

research Serum Level of Interleukin-15 in Active Alopecia Areata Patients and Its Relation to Age, Sex, and Disease Severity

14 citations , January 2020 in “Advances in Dermatology and Allergology”

This study found that elevated serum levels of IL-15 in active alopecia areata patients are correlated with disease severity, suggesting it plays a role in disease pathogenesis.

research Frontiers in Alopecia Areata Pathobiology Research

55 citations , October 2019 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology”

This review discusses emerging research areas in alopecia areata pathobiology, highlighting the potential roles of unconventional immune cells and the need for more targeted therapeutic strategies, but reports no new experimental results.

research An Integrated Model of Alopecia Areata Biomarkers Highlights Both TH1 and TH2 Upregulation

58 citations , July 2018 in “Journal of Allergy and Clinical Immunology”

Alopecia areata severity is linked to increased TH1 and TH2 activity.

research Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients

48 citations , November 2017 in “Journal of the American Academy of Dermatology”

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

Alopecia Areata Profiling Shows TH1, TH2, and IL-23 Cytokine Activation Without Parallel TH17/TH22 Skewing

research Experimental Evaluation of Ebastine, a Second-Generation Antihistamine, as a Supportive Medication for Alopecia Areata

35 citations , March 2010 in “Journal of Dermatological Science”

Ebastine may help regrow hair in alopecia areata patients.

research Maintenance of Hair Follicle Immune Privilege Is Linked to Prevention of NK Cell Attack

253 citations , December 2007 in “Journal of Investigative Dermatology”

This study suggests that human hair follicles may actively suppress natural killer cells, which contrasts with the observed defects in NK cell regulation in alopecia areata.